New Data Further Strengthens Case for Microdosing in Drug Development
News Jun 24, 2008
Xceleron has announced that preliminary results from the European Union Microdose AMS Partnership Programme (EUMAPP) further endorses the growing body of microdose data that predicts pharmacological dose ADME/PK outcomes.
The EUMAPP consortium presented preliminary results from the 30-month, €2m project at the EUFEPS Conference in Bad Homburg, Germany on 16 June.
The compounds selected for EUMAPP were chosen to rigorously test the predictability of human microdosing by studying drugs that exhibited properties in humans that are difficult to predict in animal or in vitro models and drugs with properties that, it was suspected, might be difficult to predict at a therapeutic dose from microdose data.
On reviewing the preliminary EUMAPP data Dr. Colin Garner, President and CEO of Xceleron and Chair of the EUMAPP steering committee commented: “The outputs of the programme need to undergo rigorous scrutiny and detailed interpretation but the early indications are that results strongly endorse the ability of microdosing to provide valuable human data at the earliest stages of exploratory clinical development”. He added: “We are proud to be associated with EUMAPP and congratulate the members of the consortium for a job well done”.
In the final presentation summarizing the EUMAPP workshop, Dr. Roeline Jochemsen, Director of Clinical Pharmacokinetics & Pharmacometrics at Institut de Recherches Internationales Servier concluded: “The EUMAPP study provides increased confidence in the predictivity of Microdosing”.
Professor Malcolm Rowland, Scientific Advisor to the EUMAPP consortium observed: “Generally the EUMAPP results are sufficiently encouraging to continue to support the view that, applied intelligently, microdosing coupled with AMS, offers an additional tool to facilitate earlier than otherwise possible decisions in candidate selection”.
3-D Tissue Model of Developing Heart Could Aid Drug Safety Testing for Pregnant WomenNews
The heart is the first organ to develop in the womb and the first cause of concern for many parents. Parents and doctors often have to consider the mother's health as well as the potential risk regarding how medication could affect their baby."We can try to rebuild the shape of the early development heart in the lab," said Professor Zhen Ma. "It mimics the very early stage, during the embryo genesis - how the heart was formed."READ MORE
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
'Body-on-a-Chip' Could Advance Drug EvaluationNews
MIT engineers have developed new technology that could be used to evaluate new drugs and detect possible side effects before the drugs are tested in humans. Using a microfluidic platform that connects engineered tissues from up to 10 organs, the researchers can accurately replicate human organ interactions for weeks at a time.READ MORE
Comments | 0 ADD COMMENT
World Congress on Pathology and Laboratory Medicine
Sep 10 - Sep 11, 2018
10th International Conference on Mass Spectrometry and Chromatography
Oct 08 - Oct 09, 2018